• Jupiter Neurosciences dosed the first patient in its Phase 2a RESET trial of JOTROL for Parkinson’s disease.
• Results have not been presented; the study is expected to generate safety, drug-exposure, and biomarker readouts later.
• The trial aims to assess whether JOTROL is tolerated in patients while showing signs of biological activity relevant to Parkinson’s disease.
• Management also launched a strategic review, hiring Tungsten Advisors to pursue partnering or a broader transaction to monetize programs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jupiter Neurosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610061115PRIMZONEFULLFEED9840581) on October 06, 2026, and is solely responsible for the information contained therein.